A reliance on vaccines in short supply and questions over their best use are hampering efforts to curb the global spread of monkeypox which has hit dozens of countries for the first time, health officials say.
Danish biotech firm Bavarian Nordic said on Thursday it has signed up a U.S.-based manufacturer to package its Jynneos monkeypox vaccine and the production is expected to begin later this year.
The United States will boost its supply of monkeypox vaccine by making an additional 1.8 million doses of Bavarian Nordic’s Jynneos vaccine available for ordering starting Aug. 22, the White House said on Thursday.
Cases of monkeypox are growing at an alarming rate and Bavarian Nordic, the company that owns Jynneos, one of the two approved vaccines, may no longer be able to keep up, according to a report by Bloomberg.
The U.S. government said on Monday it will provide states with up to 442,000 doses of Bavarian Nordic’s Jynneos vaccine to combat the outbreak of monkeypox disease.
Health officials in Europe are discussing whether to follow a move by the United States to stretch out scarce monkeypox vaccine supplies, with the World Health Organization calling for more data.
Drugmaker Bavarian Nordic said U.S. and European regulators have approved the use of Jynneos vaccine doses made at the company’s plant in Denmark as global efforts to tackle the monkeypox outbreak pick up pace.
British health agencies have secured funding to develop a standardized approach to test the performance of vaccines being used or in development against monkeypox, days after the World Health Organization (WHO) labeled the growing outbreak a global health emergency.
Bavarian Nordic, the Danish company behind the vaccine being used to try to stem a global outbreak of monkeypox, is in talks to potentially expand production capacity, its CEO said on Monday.
The approval comes just one day after the World Health Organization issued a high-level alert declaring the rapidly spreading monkeypox outbreak as a global health emergency.